Go Pro
NASDAQ:HSCS

HeartSciences Q4 2026 Earnings Report

HeartSciences logo
$4.30 +0.41 (+10.54%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$4.31 +0.01 (+0.21%)
As of 10/2/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HeartSciences EPS Results

Actual EPS
-$0.88
Consensus EPS
-$0.66
Beat/Miss
Missed by -$0.22
One Year Ago EPS
N/A

HeartSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.05 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

HeartSciences Announcement Details

Quarter
Q4 2026
Time
Before Market Opens
Conference Call Date
Thursday, July 23, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

HeartSciences' Q2 2027 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 16, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

HeartSciences Earnings Headlines

HeartSciences Extends Loan Terms Amid Pending Merger
Fortitude Appoints Kimberly Pittman as Chief Legal Officer
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS), Inc. is a medical technology company focused on improving the detection and management of cardiovascular disease. The company develops electrocardiography (ECG) technologies intended to provide clinicians with additional information about cardiac function using a test that is widely available in healthcare settings.

Its principal technology is the MyoVista wavECG system, which applies proprietary signal-processing methods, including wavelet analysis, to standard 12-lead ECG data. The platform is designed to identify indicators of cardiac dysfunction, including abnormalities associated with diastolic dysfunction, and to support physicians in evaluating patients for potential heart disease.

HeartSciences markets its products to healthcare providers and is pursuing applications across cardiology, primary care and other clinical settings. The company was previously known as Heart Test Laboratories and trades on the Nasdaq under the symbol HSCS. Its corporate operations are based in the United States, with its technologies intended for use in domestic and international healthcare markets.

View HeartSciences Profile